The role of sublingual sufentanil nanotabs for pain relief.
The authors discuss a novel patient controlled analgesia system utilizing a preprogrammed device that delivers a small submucosal tablet of sufentanil. This submucosal sufentanil system is not yet commercially available. A literature review of the current patient controlled analgesia systems and current information of this device are discussed. This novel device has the potential to enhance patient safety as it is preprogrammed and delivers a standard dose of sufentanil, a rapidly acting opioid devoid of active metabolites.